AAFCO’s updated model labeling guidelines put pet calming collar benefit claims and use instructions under closer review, raising the proof burden for brands selling into retail and veterinary channels.
The report says buyers already weigh safety, behavior and health-benefit evidence near launch decisions, so suppliers with weak documentation risk slower approvals, relabeling or stalled account expansion.
USD 612.6 million in 2026 is projected to grow to USD 1.50 billion by 2036 at a 9.4% CAGR, but demand is expected to develop unevenly as larger buyers require stricter evidence before switching suppliers.
North America is estimated to hold a 36.6% regional share in 2026, while India posts the fastest profiled country CAGR at 8.4%, underscoring how compliance and channel requirements will shape where growth materializes.